Download Full eBooks in PDF
How Increased Competition From Generic Drugs Has Affected Prices And Returns In The Pharmaceutical Industry Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of How Increased Competition From Generic Drugs Has Affected Prices And Returns In The Pharmaceutical Industry book. This book definitely worth reading, it is an incredibly well-written.
Author : Anonim
Publisher : U.S. Government Printing Office
Page : 94 pages
File Size : 53,5 Mb
Release : 1998
Category : Business & Economics
ISBN : PURD:32754071785707
Author : Anna Cook
Publisher : Unknown
Page : 75 pages
File Size : 42,8 Mb
Release : 1998-11-01
Category : Electronic
ISBN : 0788173510
Examines the extent to which competition from generic drugs has increased since 1984, when the Drug Price Competition & Patent Term Restoration Act (also known as the Hatch-Waxman Act) created an abbreviated approval process for generic prescription drugs & at the same time extended patent terms for innovator drugs. Also analyzes how that competition has affected the returns from developing a drug. Contents: the effect of managed care on the pharmaceutical market; pricing & competition in the pharmaceutical market; & the effects of the Hatch-Waxman act on the returns from innovation. Charts & tables.
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Publisher : National Academies Press
Page : 235 pages
File Size : 55,5 Mb
Release : 2018-03-01
Category : Medical
ISBN : 9780309468084
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : Meir Statman
Publisher : A E I Press
Page : 106 pages
File Size : 49,6 Mb
Release : 1983
Category : Business & Economics
ISBN : STANFORD:36105037524589
Author : Congressional Budget Office
Publisher : Lulu.com
Page : 65 pages
File Size : 40,6 Mb
Release : 2013-06-09
Category : Electronic
ISBN : 9781304121448
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Author : Institute of Medicine,Committee on Technological Innovation in Medicine
Publisher : National Academies Press
Page : 225 pages
File Size : 50,8 Mb
Release : 1991-02-01
Category : Medical
ISBN : 9780309044912
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author : Anonim
Publisher : DIANE Publishing
Page : 129 pages
File Size : 49,5 Mb
Release : 2002
Category : Electronic
ISBN : 9781428951938
Author : Anonim
Publisher : Unknown
Page : 234 pages
File Size : 48,8 Mb
Release : 2000
Category : Drugs
ISBN : STANFORD:36105028431273
On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).
Author : Robert B. Helms
Publisher : A E I Press
Page : 408 pages
File Size : 52,9 Mb
Release : 1996
Category : Business & Economics
ISBN : UOM:39015037832337
The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products - even though new technologies have increased both the cost and the medical attractiveness of those products. Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research. This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.
Author : Min Ding,Jehoshua Eliashberg,Stefan Stremersch
Publisher : Springer Science & Business Media
Page : 768 pages
File Size : 52,6 Mb
Release : 2013-10-31
Category : Medical
ISBN : 9781461478010
The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike.
Author : Katherine Eban
Publisher : HarperCollins
Page : 512 pages
File Size : 40,6 Mb
Release : 2020-06-23
Category : Medical
ISBN : 9780063054103
A NEW YORK TIMES BESTSELLER New York Times 100 Notable Books of 2019 New York Public Library Best Books of 2019 Kirkus Reviews Best Health and Science Books of 2019 Science Friday Best Books of 2019 New postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
Author : United States. Federal Trade Commission. Bureau of Consumer Protection
Publisher : Unknown
Page : 390 pages
File Size : 42,7 Mb
Release : 1979
Category : Drugs
ISBN : UOM:39015008517792
Author : Anonim
Publisher : DIANE Publishing
Page : 380 pages
File Size : 52,7 Mb
Release : 1993
Category : Drugs
ISBN : 0788104683
Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.
Author : Elizabeth R. Nesbitt
Publisher : DIANE Publishing
Page : 246 pages
File Size : 40,7 Mb
Release : 2000
Category : Drugs
ISBN : 9781457823428
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Board on Health Care Services
Publisher : National Academies Press
Page : 103 pages
File Size : 49,7 Mb
Release : 2020-01-27
Category : Medical
ISBN : 9780309498517
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.